What is claimed is:

1. A compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:



I

wherein

n is 1 or 2;

$R^1$ is selected from –H, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, -$CH_2$-$R^8$, -C(=O)-NH-$R^7$, -C(=S)-NH-$R^7$, -C(=O)-O-$R^7$, -S(=O)$_2$-$R^6$, and -C(=O)-$R^5$, wherein $R^5$, $R^6$, $R^7$ and $R^8$ are independantly selected from $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-4}$alkyl, wherein said $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-4}$alkyl used in defining $R^1$, $R^5$, $R^6$, $R^7$ or $R^8$ are optionally substituted with one or more groups selected from –OH, -CHO, -$NH_2$, -NHR, -$NR_2$, $C_{1-6}$alkyl, -C(=O)-R, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, -$NO_2$, $C_{1-6}$alkoxy and halogen, or disubstituted with –O-$CH_2$-O- to form a fused ring;

$R^2$ is selected from –H and $C_{1-6}$alkyl;

$R^3$ and $R^4$ are independently selected from –H, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-4}$alkyl, wherein said $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl,

$C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-4}$alkyl are optionally substituted with one or more groups selected from –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, $-NO_2$, $C_{1-6}$alkoxy and halogen; or $R^3$ and $R^4$ together with the nitrogen connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more groups selected from benzyl, –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, $-NO_2$, $C_{1-6}$alkoxy, and halogen;

Ar is selected from $C_{6-10}$aryl and $C_{3-6}$heteroaryl, wherein said $C_{6-10}$aryl and $C_{3-6}$heteroaryl are optionally substituted with one or more groups selected from –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, $-NO_2$, $C_{1-6}$alkoxy, and halogen; and

R is $C_{1-6}$alkyl.

2. A compound according to claim 1,

wherein n is 1 or 2;

$R^1$ is selected from $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $-CH_2-R^8$, -C(=O)-NH-$R^7$, -C(=S)-NH-$R^7$, $-S(=O)_2-R^6$, and -C(=O)-$R^5$, wherein $R^5$, $R^6$, $R^7$ and $R^8$are independantly selected from $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-2}$alkyl, phenyl, phenyl-$C_{1-2}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-2}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-2}$alkyl, wherein said $C_{1-4}$alkyl, $C_{2-4}$alkenyl, $C_{3-6}$alkyl, phenyl, phenyl-$C_{1-2}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-2}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-2}$alkyl used in defining $R^1$, $R^5$, $R^6$, $R^7$or $R^8$ are optionally substituted with one or more groups selected from –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, $C_{1-3}$alkyl, -C(=O)-R, -C(=O)-OR, -SR, $-CF_3$, -CN, methoxy, ethoxy, fluoro and chloro, or disubstituted with $-O-CH_2-O-$ to form a fused ring;

$R^2$ is selected from –H, methyl and ethyl;

$R^3$ and $R^4$ are independently selected from –H, $C_{1-4}$alkyl, $C_{2-4}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-2}$alky, phenyl, phenyl-$C_{1-2}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-2}$alkyl, $C_{3-6}$heteroaryl, and

$C_{3-6}$heteroaryl-$C_{1-2}$alkyl, wherein said $C_{1-4}$alkyl, $C_{2-4}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-2}$alky, phenyl, phenyl-$C_{1-2}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-2}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-2}$alkyl are optionally substituted with one or more groups selected from -CHO, $-NH_2$, -NHR, $-NR_2$, $C_{1-3}$alkyl, -C(=O)-OR, $-CF_3$, -CN, methoxy, ethoxy, fluoro and chloro; or $R^3$ and $R^4$ together with the nitrogen connected thereto in formula I form a heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted with one or more groups selected from benzyl, -CHO, $C_{1-3}$alkyl, -C(=O)-OR, $-CF_3$, -CN, methoxy, ethoxy, fluoro and chloro;

Ar is selected from phenyl and five or six-membered $C_{3-5}$heteroaryl, wherein said phenyl and five or six-membered $C_{3-5}$heteroaryl are optionally substituted with one or more groups selected from $C_{1-3}$alkyl, -C(=O)-OR, $-CF_3$, -CN, methoxy, ethoxy, fluoro and chloro; and

R is $C_{1-3}$alkyl.

3. A compound according to claim 1,

wherein n is 1 or 2;

$R^1$ is selected from $-CH_2-R^8$, -C(=O)-NH-$R^7$, -C(=S)-NH-$R^7$, $-S(=O)_2-R^6$, and -C(=O)-$R^5$, wherein $R^5$, $R^6$, $R^7$ and $R^8$are independantly selected from $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-2}$alkyl, phenyl, benzyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-2}$alkyl, $C_{3-6}$heteroaryl, wherein said $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-2}$alkyl, phenyl, benzyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-2}$alkyl, $C_{3-6}$heteroaryl are optionally substituted with one or more groups selected from methyl, ethyl, -C(=O)-$CH_3$, -C(=O)-$OCH_3$, -C(=O)-$OCH_2-CH_3$, $-SCH_3$, -CN, methoxy, ethoxy, fluoro and chloro, or said phenyl or benzyl is optionally disubstituted with $-O-CH_2-O-$ to form a fused ring;

$R^2$ is selected from –H, methyl and ethyl;

$R^3$ and $R^4$ are independently selected from –H, methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl,

thienyl-methyl, wherein said methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl, thienyl-methyl are optionally substituted with one or more groups selected from dimethylamino, diethylamino, diisopropylamino, methyl, ethyl, methoxy, or $R^3$ and $R^4$ together with the nitrogen connected thereto in formula I form a heterocycloalkyl ring selected from piperidine, azetidine, piperazine, pyrrolidine and morpholine, wherein said piperidine, azetidine, piperazine, pyrrolidine and morpholine is optionally substituted with one or more groups selected from benzyl, methyl and -CHO; and

Ar is selected from phenyl, pyridyl, furyl and thienyl, wherein said phenyl, pyridyl, furyl and thienyl are optionally substituted with one or more methoxy or ethoxy.

4. A compound according to claim 1,

wherein n is 1 or 2;

$R^1$ is selected from $-CH_2-R^8$, $-C(=O)-NH-R^7$, $-C(=S)-NH-R^7$, $-S(=O)_2-R^6$, and $-C(=O)-R^5$, wherein $R^5$, $R^6$, $R^7$ and $R^8$are independantly selected from methyl, ethyl, isopropyl, 1-propyl, 2-methyl-1-propyl, 3-methyl-1-butyl, 2-ethyl-1-butyl, 1-butyl, 1-propen-3-yl, 4-methyl-2-penten-1-yl, 3-methyl-2-buten-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl-methyl, phenyl, benzyl, 4-morpholinyl-ethyl, tetrahydrothiopyran-4-yl-ethyl, furyl, isoxazolyl, pyridyl, thienyl, pyrazolyl, imidazolyl, and pyrrolyl, wherein said methyl, ethyl, isopropyl, 1-propyl, 2-methyl-1-propyl, 3-methyl-1-butyl, 2-ethyl-1-butyl, 1-butyl, 1-propen-3-yl, 4-methyl-2-penten-1-yl, 3-methyl-2-buten-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl-methyl, phenyl, benzyl, 4-morpholinyl-ethyl, tetrahydrothiopyran-4-yl-ethyl, furyl, isoxazolyl, pyridyl, thienyl, pyrazolyl, imidazolyl, and pyrrolyl are optionally substituted with one or more groups selected from methyl, ethyl, $-C(=O)-CH_3$, $-C(=O)-OCH_3$, $-C(=O)-OCH_2-CH_3$, $-SCH_3$, -CN, methoxy, ethoxy, fluoro and chloro, or said phenyl or benzyl is optionally disubstituted with $-O-CH_2-O-$ to form a fused ring;

$R^2$ is selected from –H, methyl and ethyl;

$R^3$ and $R^4$ are independently selected from –H, methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl, thienyl-methyl, wherein said methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl, thienyl-methyl are optionally substituted with one or more groups selected from dimethylamino, diethylamino, diisopropylamino, methyl, ethyl, methoxy, or $R^3$ and $R^4$ together with the nitrogen connected thereto in formula I form a heterocycloalkyl ring selected from piperidine, azetidine, piperazine, pyrrolidine and morpholine, wherein said piperidine, azetidine, piperazine, pyrrolidine and morpholine is optionally substituted with one or more groups selected from benzyl, methyl and -CHO; and

Ar is selected from phenyl, 4-ethoxyphenyl, 4-methoxyphenyl, pyridyl, furyl and thienyl.

5. A compound according to claim 1, wherein the compound is selected from:

1-Benzoyl-4-phenyl-8-(pyrrolidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

1-Benzoyl-*N*-[2-(diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*,*N*-Diethyl-4-phenyl-1-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

1-Benzyl-*N*-[2-(diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-[2-(Diethylamino)ethyl]-1-(2-furylmethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-[2-(Diethylamino)ethyl]-4-phenyl-1-(pyridin-3-ylmethyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-[2-(Diethylamino)ethyl]-1-[(1-methyl-1*H*-pyrrol-2-yl)methyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

1-(3-Furylmethyl)-8-(morpholin-4-ylcarbonyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
*N*-[2-(Diisopropylamino)ethyl]-1-[(5-ethyl-2-furyl)methyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
4-Phenyl-8-(pyrrolidin-1-ylcarbonyl)-1-(thien-2-ylmethyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
*N*,*N*-Diethyl-4-phenyl-1-(thien-2-ylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
and pharmaceutically acceptable salts thereof.

6. A compound according to any one of claims 1-5 for use as a medicament.

7. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the therapy of pain, anxiety or functional gastrointestinal disorders.

8. A pharmaceutical composition comprising a compound according to any one of claims 1-5 and a pharmaceutically acceptable carrier.

9. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.

10. A method for the therapy of functional gastrointestinal disorders in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.

11. A process for preparing a compound of formula I, comprising:



I

reacting a compound of formula II with a compound selected from $R^5$-C(=O)-Cl, $R^6$-S(=O)$_2$-Cl, $R^7$-NCO, $R^7$-NCS and $R^8$CHO:



II

wherein

n is 1 or 2;

$R^1$ is selected from -$CH_2$-$R^8$, -C(=O)-NH-$R^7$, -C(=S)-NH-$R^7$, -S(=O)$_2$-$R^6$, and -C(=O)-$R^5$, wherein $R^5$, $R^6$, $R^7$ and $R^8$ are independantly selected from $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-4}$alkyl, wherein said $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-4}$alkyl are optionally substituted with one or more groups selected from –OH, -CHO, -$NH_2$, -NHR, -$NR_2$, $C_{1-6}$alkyl, -C(=O)-R, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, -$NO_2$, $C_{1-6}$alkoxy and halogen, or disubstituted with –O-$CH_2$-O- to form a fused ring;

$R^2$ is selected from –H and $C_{1-6}$alkyl;

$R^3$ and $R^4$ are independently selected from –H, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and

$C_{3-6}$heteroaryl-$C_{1-4}$alkyl, wherein said $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-4}$alkyl are optionally substituted with one or more groups selected from –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, $-NO_2$, $C_{1-6}$alkoxy and halogen; or $R^3$ and $R^4$ together with the nitrogen connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more groups selected from benzyl, –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, $-NO_2$, $C_{1-6}$alkoxy, and halogen;

Ar is selected from $C_{6-10}$aryl and $C_{3-6}$heteroaryl, wherein said $C_{6-10}$aryl and $C_{3-6}$heteroaryl are optionally substituted with one or more groups selected from –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, $-NO_2$, $C_{1-6}$alkoxy, and halogen; and

R is $C_{1-6}$alkyl.

12. A process for preparing a compound of formula I, comprising:



I

reacting a compound of formula III with $R^3R^4NH$:



III

wherein

n is 1 or 2;

$R^1$ is selected from –C(=O)-O-$C_{1-6}$alkyl and –C(=O)-O-$C_{2-6}$alkenyl;

$R^2$ is selected from –H and $C_{1-6}$alkyl;

$R^3$ and $R^4$ are independently selected from –H, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-4}$alkyl, wherein said $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-4}$alkyl are optionally substituted with one or more groups selected from –OH, -CHO, -$NH_2$, -NHR, -$NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, -$NO_2$, $C_{1-6}$alkoxy and halogen; or $R^3$ and $R^4$ together with the nitrogen connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more groups selected from benzyl, –OH, -CHO, -$NH_2$, -NHR, -$NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, -$NO_2$, $C_{1-6}$alkoxy, and halogen;

Ar is selected from $C_{6-10}$aryl and $C_{3-6}$heteroaryl, wherein said $C_{6-10}$aryl and $C_{3-6}$heteroaryl are optionally substituted with one or more groups selected from –OH, -CHO, -$NH_2$, -NHR, -$NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, -$NO_2$, $C_{1-6}$alkoxy, and halogen; and

R is $C_{1-6}$alkyl.

13. A process for preparing a compound of formula IV, comprising:




IV

reacting a compound of formula V with a compound of formula VI:



V



VI

wherein

n is 1 or 2;

$R^1$ is selected from –C(=O)-O-$C_{1-6}$alkyl and –C(=O)-O-$C_{2-6}$alkenyl;

$R^9$ is $C_{1-6}$alkyl;

Ar is selected from $C_{6-10}$aryl and $C_{3-6}$heteroaryl, wherein said $C_{6-10}$aryl and $C_{3-6}$heteroaryl are optionally substituted with one or more groups selected from –OH, -CHO, -$NH_2$, -NHR, -$NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, -$NO_2$, $C_{1-6}$alkoxy, and halogen; and

R is $C_{1-6}$alkyl.

14. A compound of formula II:



II

wherein

n is 1 or 2;

$R^2$ is selected from –H and $C_{1-6}$alkyl;

$R^3$ and $R^4$ are independently selected from –H, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-4}$alkyl, wherein said $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{3-6}$cycloalkyl,

$C_{3-6}$cycloalkyl-$C_{1-4}$alkyl, $C_{6-10}$aryl, $C_{6-10}$aryl-$C_{1-4}$alkyl, $C_{3-6}$heterocycloalkyl, $C_{3-6}$heterocycloalkyl-$C_{1-4}$alkyl, $C_{3-6}$heteroaryl, and $C_{3-6}$heteroaryl-$C_{1-4}$alkyl are optionally substituted with one or more groups selected from –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, $-NO_2$, $C_{1-6}$alkoxy and halogen; or $R^3$ and $R^4$ together with the nitrogen connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more groups selected from benzyl, –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, $-NO_2$, $C_{1-6}$alkoxy, and halogen;

Ar is selected from $C_{6-10}$aryl and $C_{3-6}$heteroaryl, wherein said $C_{6-10}$aryl and $C_{3-6}$heteroaryl are optionally substituted with one or more groups selected from –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, $C_{1-6}$alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated $C_{1-6}$alkyl, -CN, $-NO_2$, $C_{1-6}$alkoxy, and halogen; and

R is $C_{1-6}$alkyl.

15. A compound according to claim 14, wherein the compound is selected from:

8-[(4-Methylpiperazin-1-yl)carbonyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

8-(Morpholin-4-ylcarbonyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

4-Phenyl-8-(pyrrolidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

*N*-(Cyclopropylmethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-Phenyl-*N*-(tetrahydrofuran-2-ylmethyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-(2-Methoxyethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-[2-(Diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*,*N*-Diethyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-(4-Ethoxyphenyl)-8-[(4-methylpiperazin-1-yl)carbonyl]-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

4-(4-Ethoxyphenyl)-8-(morpholin-4-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

4-(4-Ethoxyphenyl)-8-(pyrrolidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

*N*-(Cyclopropylmethyl)-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-(4-Ethoxyphenyl)-*N*-(2-furylmethyl)-*N*-methyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-(2-Methoxyethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-[2-(Diethylamino)ethyl]-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

(4-(4-Ethoxyphenyl)-*N*,*N*-diethyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-[2-(Diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

Piperazine, 1-[(2,3,3a,4,5,9b-hexahydro-4-phenyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)carbonyl]-4-methyl-;

Piperazine, 1-[[2,3,3a,4,5,9b-hexahydro-4-(4-methoxyphenyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl]carbonyl]-4-methyl-;

Piperazine, 1-[[2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl]carbonyl]-4-methyl-;

1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[(1-ethyl-2-pyrrolidinyl)methyl]-2,3,3a,4,5,9b-hexahydro-4-phenyl-;

1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-4-(4-methoxyphenyl)-;

1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[(1-ethyl-2-pyrrolidinyl)methyl]-2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[(1-ethyl-2-pyrrolidinyl)methyl]-2,3,3a,4,5,9b-hexahydro-4-(4-methoxyphenyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-(4-methoxyphenyl)-*N*-(2-pyridinylmethyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-phenyl-*N*-(2-pyridinylmethyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-*N*-(2-pyridinylmethyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-;
1-Piperazinecarboxaldehyde, 4-[(2,3,3a,4,5,9b-hexahydro-4-phenyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)carbonyl]-;
1-Piperazinecarboxaldehyde, 4-[[2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl]carbonyl]-;
Piperazine, 1-[(2,3,3a,4,5,9b-hexahydro-4-phenyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)carbonyl]-4-(phenylmethyl)-;
Piperazine, 1-[[2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl]carbonyl]-4-(phenylmethyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-[bis(1-methylethyl)amino]ethyl]-2,3,3a,4,5,9b-hexahydro-4-phenyl-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-[bis(1-methylethyl)amino]ethyl]-2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(dimethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(dimethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-4-phenyl-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-*N*-methyl-4-phenyl-;

1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-*N*-methyl-4-(2-pyridinyl)-;

1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-phenyl-*N*-[2-(4-thiomorpholinyl)ethyl]-;

1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-*N*-[2-(4-thiomorpholinyl)ethyl]-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-methoxyethyl)-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopentyl-5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopropyl-5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-thienylmethyl)-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-*N*-[(5-methyl-2-furanyl)methyl]-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-*N*,*N*-diethyl-1,2,3,4,4a,5,6,10b-octahydro-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-*N*-[2-(1-pyrrolidinyl)ethyl]-;

Pyrrolidine, 1-[(1,2,3,4,4a,5,6,10b-octahydro-5-phenylbenzo[*h*][1,6]naphthyridin-9-yl)carbonyl]-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-methoxyethyl)-5-phenyl-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopentyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopropyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-*N*-(2-thienylmethyl)-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-*N*-[(5-methyl-2-furanyl)methyl]-5-phenyl-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*,*N*-diethyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-*N*-[2-(1-pyrrolidinyl)ethyl]-;

Pyrrolidine, 1-[(6-ethyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenylbenzo[*h*][1,6]naphthyridin-9-yl)carbonyl]-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 6-ethyl-1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-methoxyethyl)-5-phenyl-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopentyl-6-ethyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;

*N*-Cyclopropyl-6-ethyl-5-phenyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;

6-Ethyl-5-phenyl-*N*-(thien-2-ylmethyl)-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;

6-Ethyl-*N*-[(5-methyl-2-furyl)methyl]-5-phenyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;

*N*,*N*,6-Triethyl-5-phenyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;

6-Ethyl-5-phenyl-*N*-(2-pyrrolidin-1-ylethyl)-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;

4-(4-Ethoxyphenyl)-*N*,*N*-dimethyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-(4-Ethoxyphenyl)-*N*-methyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-(Cyclopropylmethyl)-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Cyclobutyl-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Cyclopropyl-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Allyl-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-(4-Ethoxyphenyl)-8-(piperidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

8-(Azetidin-1-ylcarbonyl)-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

*N*,*N*-Dimethyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Methyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-(Cyclopropylmethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Cyclobutyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Cyclopropyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

(*N*-Allyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-Phenyl-8-(piperidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

8-(Azetidin-1-ylcarbonyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

4-(2-Furyl)-*N*,*N*-dimethyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-(2-Furyl)-*N*-methyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-(Cyclopropylmethyl)-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Cyclobutyl-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Cyclopropyl-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Allyl-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-(2-Furyl)-8-(piperidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

8-(Azetidin-1-ylcarbonyl)-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

*N*,*N*-Dimethyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Methyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-(Cyclopropylmethyl)-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Cyclobutyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Cyclopropyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

*N*-Allyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

8-(Piperidin-1-ylcarbonyl)-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

8-(Azetidin-1-ylcarbonyl)-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

*N*-[2-(Dimethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide; and pharmaceutically acceptable salts thereof.